Comment on Human Genome shares plunge on study results - Forbes

Human Genome shares plunge on study results - Forbes

HealthKnowItAllHuman Genome shares plunge on study resultsForbesAP , 03.09.09, 12:10 PM EDT Shares of drug developer Human Genome Sciences Inc. were nearly cut in half Monday as Wall Street expressed disappointment over the company's latest study results for the developing hepatitis C drug Albuferon.Human Genome Sciences drug succeeds in trial Bizjournals.comPositive Results For Human Genome Experimental Hepatitis C Drug HealthKnowItAllTheStreet.com - FierceBiotech - MSNBC - PR Newswire (press release)all 41 news articles

 

Comment On This Story

Welcome to Wopular!

Welcome to Wopular

Wopular is an online newspaper rack, giving you a summary view of the top headlines from the top news sites.

Senh Duong (Founder)
Wopular, MWB, RottenTomatoes

Subscribe to Wopular's RSS Fan Wopular on Facebook Follow Wopular on Twitter Follow Wopular on Google Plus

MoviesWithButter : Our Sister Site

More News